Cell therapy

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Register now to hear from the CGT experts

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Challenges and solutions in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Experts explore developments in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Auditory pathway
#Cell therapy #Hearing Loss #Lineage Cell Therapeutics #Transplant

Research collaboration targets cell-based therapy for hearing loss

Lineage Cell Therapeutics has entered a research collaboration with and through an investment from William Demant Invest (WDI), the holding company for William Demant Foundation’s investment activities and a majority shareholder of hearing healthcare company, Demant.  The parties will jointly advance Lineage’s auditory neuronal cell transplant, ReSonance… Read More

#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Watch now: Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

CAR-T cell attacking cancer
#CAR-T #Cell therapy #In vivo #Kite Pharma #Mergers and acquisitions

Kite acquires in vivo CAR-T developer for $350 million

Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.  The acquisition complements Kite’s focus on cell therapy by incorporating Interius’s integrating in vivo platform.   This… Read More

#Business & Investment #News

#Cancer vaccine #CAR-T #Cell therapy #Immunotherapy #Oncology

New DDW Highlights podcast: 19 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week has seen some incredible advances in immunotherapy, including the development of a therapy… Read More

#News

Non-Hodgkins lymphoma
#CAR-T #Cell therapy #Lymphoma #Natural killer cells #Phase I trial

CAR-NK therapy treats incurable lymphoma in Phase I trial

In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL).  QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More

#Cancer Research #News #Trending News

#Cancer vaccine #CAR-T #Cell therapy #Immunotherapy #Oncology

This week in drug discovery (11-15 August) 

News round-up for 11-15 August by DDW Senior Digital Content Editor Diana Turner. This week has seen some incredible advances in immunotherapy, including the development of a therapy that combines natural killer and CAR-T cells, and an off-the-shelf cancer vaccine that could revolutionise treatment for patients with one… Read More

#News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Cell therapy #FDA #Galapagos #Lymphoma #Oncology

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).   To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has… Read More

#News #Regulatory

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

#Adaptimmune Therapeutics #Cell therapy #Mergers and acquisitions

Adaptimmune sells cell therapies to US WorldMeds

Adaptimmune Therapeutics has entered into a definitive agreement for the sale of Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds.   The purchase price is $55 million in cash to be paid upon consummation of the sale, with up to $30 million in potential future payments… Read More

#Business & Investment #News

European Commission
#Autolus #CAR-T #Cell therapy #European Commission #Leukaemia #Oncology

Autolus Therapeutics’ CAR-T therapy gets EU green light

The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).  The EC approval was based on the results of the FELIX study, an open-label, multi… Read More

#News #Regulatory

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights podcast: 7 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that… Read More

#News